



PPD Celebrates 25 Years of Advancing Drug Development

Company's heritage of excellence continues to drive execution, quality and innovation

WILMINGTON, N.C. (February 2, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it is celebrating 25 years as one of the world's leading contract research organizations, building upon its strong foundation and history of helping clients deliver safe, effective medicines to patients.

Founded in 1985 as a one-person consulting firm by Fred Eshelman, PPD went public in early 1996. Over the past [25 years](#), PPD has strengthened its services, technologies and geographic reach through acquisitions and organic growth to meet growing client demand. Today, PPD employs more than 10,500 professionals with 85 offices, clinics and labs in 40 countries. It delivers a full range of discovery, development and laboratory services to biopharmaceutical and medical device companies and academic and government organizations across the globe.

"From day one, our commitment at PPD has been to deliver exceptional service, consistent quality and innovative ideas that help our clients and partners achieve their research and development goals," said Eshelman, executive chairman of PPD. "We take pride in what we have achieved in our first quarter century and salute our employees who consistently bring expertise, dedication and a passion for doing what's right for our clients, patients and sites."

With its solid financial performance, broad global reach and strong client focus, PPD is well-positioned to continue to address challenges facing biopharmaceutical companies. The rising cost of drug development, globalization in clinical research and increased scrutiny by regulatory agencies such as the Food and Drug Administration are areas where PPD is pursuing new approaches, innovative alliances and unique partnering opportunities to face these challenges.

"PPD has a strong history and legacy of assisting our clients with their drug discovery and development needs," said David Grange, chief executive officer, PPD. "As we enter into 2010, we will continue to build on this 25-year heritage and develop innovative solutions for our clients as they deliver life-changing medicines to patients."

PPD is a leading global contract research organization, celebrating 25 years of advancing drug development. We provide discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 40 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at <http://www.ppdi.com>.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the celebration of PPD's 25th anniversary, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; competition within the outsourcing industry; success in sales growth; loss of large contracts; increased cancellation rates; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; risks associated with acquisitions and investments, such as impairments; rapid technological advances that make our products and services less competitive; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+1 919 456 5890

sueann.pentecost@ppdi.com

Analysts/Investors:

Luke Heagle

+1 910 558 7585

luke.heagle@ppdi.com